ATXI

0.30000.00%
LA

Lindsay Allan Rosenwald

Executive Chairman, President & CEO

Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since October 2014. He serves as an Executive Chairman of Cyprium Therapeutics, Inc. and Founded it in 2017. Dr. Rosenwald has been Executive Chairman, Chief Executive Officer and President of Fortress Biotech, Inc. since December 19, 2013 and serves as its Director since October 2009. Dr. Rosenwald has experience in creating, financing and investing in biotechnology and life-sciences companies and has been an investment banker, venture capitalist and fund Manager. Dr. Rosenwald served as the Co-Chairman and Chief Executive Officer of Origo Acquisition Corporation from August 26, 2014 to June 10, 2016. Dr. Rosenwald joined CB Pharma Acquisition Corp in 2014. He also serves as a member of the board of directors for Baergic Bio, Inc. and Oncogenuity, Inc. Dr. Rosenwald is the Founder of Paramount BioSciences, LLC and serves as its Chairman and Chief Executive Officer. Dr. Rosenwald is the Founder of Paramount Capital Inc. and serves as its Chief Executive Officer and Chairman. Dr. Rosenwald is the Founder of Interneuron Pharmaceuticals Inc. and serves as its Chairman. He is the General Partner at Aries Domestic Fund LP. He is the Founder of Greenwich Therapeutics, Inc. Dr. Rosenwald Founded Paramount BioCapital Asset Management, Inc. He Founded Paramount BioCapital, Inc. He served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc from November 2014 to August 2015. Since November 2008, Dr. Rosenwald serves as Co-Portfolio Manager and Partner of Opus Point Partners Management, LLC (“Opus Point”), which he joined in 2009. Dr. Rosenwald had been Chief Executive Officer at Paramount BioCapital, Inc. since 1991 until 2008. Dr. Rosenwald served as Chief Executive Officer and Chairman at Paramount BioCapital Asset Management, Inc. from 1994 to 2008. He served as Chief Executive Officer and President of Avenue Therapeutics, Inc. from November 2014 to August 2015 and had been its Executive Chairman since February 2015 until March 07, 2023. He serves as Executive Director of Avenue Therapeutics, Inc. from February 2015. He serves as Executive Chairman of the Board at Helocyte Inc. From 1991 to 2008, Dr. Rosenwald served as the Chairman of Paramount BioCapital, Inc. He also served as managing Member of Paramount Biosciences LLC (and its predecessor, Paramount BioCapital Investments, LLC), an entity engaged in the research, formation and acquisition of seed-stage and distressed life science technologies and companies, identifying and evaluating a broad spectrum of therapeutic and medical technologies in order to capture innovations with significant commercial potential from 1996 to 2008. He also has biotechnology and pharmaceutical industry experience and in-depth understanding of business. He co-founded Endo Pharmaceuticals Solutions Inc. (formerly Indevus Pharmaceuticals Inc.). He was employed at Neose Technologies, Inc. He served as the Founder, Chief Executive Officer and Chairman at Paramount Capital Investments, L.L.C. Dr. Rosenwald founded numerous biopharmaceutical companies and serves as an Officer or Director at several privately held biopharmaceutical companies. Dr. Rosenwald served as the Chairman at Indevus Pharmaceuticals from February 1989 to January 19, 2000. He serves as Chairman of the Board of Paramount Capital Asset Management, Inc. Dr. Rosenwald served as Chairman of the Board of Paramount Acquisition Corp. since October 2005 until its merger with B.J.K. Inc. in October 2007. He served as Chairman of Chem Rx Corporation since June 1, 2005. He serves as a Director at Helocyte Inc. He has been Non-Executive Director of Mustang Bio, Inc. since March 13, 2015. He serves as a Member of the Board of Directors of, Avigen Inc.; BioCryst Pharmaceuticals Inc.; Titan Pharmaceuticals Inc.; VimRx Pharmaceuticals Inc.; Neose Technologies Inc. and Access Oncology. He had been a Non-Executive Director of Checkpoint Therapeutics, Inc. since November 10, 2014 until May 30, 2025. He served as a Director of Keryx Biopharmaceuticals Inc. since March 2000 until November 2006. He served as a Director of Endo Pharmaceuticals Solutions Inc. He served as a Director of Cougar Biotechnology, Inc. since May 2003 until July 18, 2007. He served as a Director of Chem Rx Corporation since June 1, 2005 until January 2008. Prior thereto, he served as a Member of the Board of Directors of Indevus Pharmaceuticals Inc. until August 29, 2003 and Sparta Pharmaceuticals since February 1991. Dr. Rosenwald serves as a Member of the Board of Directors of Aevitas Therapeutics, Inc. Caelum Biosciences, Inc. Cellvation, Inc. Journey Medical Corporation and Tamid Bio, Inc. He has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. He co-founded TG Therapeutics, Inc. Dr. Rosenwald received a B.S. in Finance from Pennsylvania State University and an M.D. from Temple University School of Medicine.

Positions